Vir Biotechnology: Fairly Valued After Phase 3 Success?
Vir Biotechnology’s hepatitis delta therapy posted 44% primary endpoint success in Phase 3, alongside a new Gilead partnership and $991.3…
Cypriot Invests NASDAQ
Vir Biotechnology, Inc.
VIR
1 story
$2B Market cap · 2026-11-05
Get VIR news in Claude, ChatGPT or your own code. See plans
Cypriot Invests 